Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

CANADA: Safe Injection Sites Planned for Montreal


Ottawa Citizen (12.17.11) - Monday, December 19, 2011

Montreal should open supervised injection sites to reduce overdoses and the spread of blood-borne diseases among injection drug users, Director of Public Health Dr. Richard Lessard said in a report released Friday. If the suggestions are accepted by the Quebec Health Department, Montreal could launch three supervised injection sites and a mobile injection center as early as next year. However, his recommendation is that most of the sites be housed in local community centers, rather than medical facilities. This is at odds with the approach taken by city government, which has stated a preference that the injection centers be located in hospitals or free community health clinics.


Copyright © 2011 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in December 19, 2011. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.